Arrowstreet Capital’s Portola Pharmaceuticals, Inc. PTLA Stock Holding History

Arrowstreet Capital’s Portfolio PTLA Stock Details PTLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-35,300	Closed	-$1.98M	–	1312
2017 Q2	$1.98M	Buy	+35,300	New	+$1.41M	0.01%	658
2014 Q2	–	Sell	-10,518	Closed	-$272K	–	1257
2014 Q1	$272K	Buy	+10,518	New	+$281K	﹤0.01%	1053

Other funds holding PTLA

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

CCM

Cadian Capital Management New York $821M AUM 14.36% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Arrowstreet Capital's PTLA Position: Q3 2017 in Review

Arrowstreet Capital sold out of Portola Pharmaceuticals, Inc. (PTLA) in Q3 2017, closing a stake of 35,300 shares — an estimated $1.98M sold.

Arrowstreet Capital first reported a position in PTLA in Q1 2014 and held it in 2 quarters. The position peaked at $1.98M in Q2 2017. 221 funds tracked by Wall St. Rank hold PTLA as of Q3 2017.

Arrowstreet Capital reported no remaining Portola Pharmaceuticals, Inc. position as of Q3 2017 after selling out during the quarter.
Arrowstreet Capital sold 35,300 Portola Pharmaceuticals, Inc. shares in Q3 2017, an estimated $1.98M.
Arrowstreet Capital first reported a position in Portola Pharmaceuticals, Inc. in Q1 2014 and held it in 2 quarters.
Arrowstreet Capital's Portola Pharmaceuticals, Inc. position peaked at $1.98M in Q2 2017.
221 funds tracked by Wall St. Rank held Portola Pharmaceuticals, Inc. as of Q3 2017.

Based on Arrowstreet Capital's 13F filing for Q3 2017, filed 14 Nov 2017.